WilmerHale Represents Generation Bio in $100M Series B Financing

WilmerHale Represents Generation Bio in $100M Series B Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing. Proceeds will be used to move Generation Bio's first two therapeutic candidates through Investigational New Drug enabling studies and to advance additional programs targeting genetic diseases of the retina, central nervous system and lungs. This follows on the heels of the company's previously announced $25 million Series A financing.

The WilmerHale team representing Generation Bio includes Stuart Falber, Stephanie Singer and Brett Bromann, with licensing counsel from Steve Barrett.

Read the press release announcing this news for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel